News

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.
Pfizer Shares Rise on CEO’s Optimism on Threatened Drug Tariffs
The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts polled by FactSet.
US groups raced to stockpile pharmaceuticals ahead of tariffs
A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include ...
Hosted on MSN14d
Pfizer CEO: 'We should not have tariffs' on pharma
Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting ... CFO David Denton said the company is already ...
BioPharma Dive14d
Pfizer’s Bourla ‘cautiously optimistic’ on looming US pharma tariffs
The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...
BioPharma Dive11d
Pharma downplays tariff threat, even as risks remain unclear
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...
Pfizer leans on cost cuts to offset falling revenue
Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...
AOL13d
What CEOs are saying about how tariffs will impact their businesses — and your wallet
Pfizer CEO Albert Bourla said the pharmaceutical ... the company behind fast food chains like Taco Bell and Pizza Hut, expects little impact from tariffs on its supply chain, CFO Chris Turner ...